Although surgery is still the most effective treatment for diffuse glioma, patients with unresectable primary, recurrent, or multicentric illness have few options. In some cases, genotyping predictions may be useful for targeted therapy. We performed pretreatment MRI scans and genetic sequencing of tumor tissue, as well as correlation analysis, to see if essential molecular genetic events linked with diffuse glioma may be predicted in advance and noninvasively. The findings revealed that the MAP-MRI model can reliably predict tumor genotyping with high robustness and diagnostic validity, implying that it could be useful in the development of more standardized treatment.
This abstract and the presentation materials are available to members only; a login is required.